EyeArt AI System for Autonomous Diabetic Retinopathy Testing
Eyenuk Inc., is a global artificial intelligence (AI) medical technology company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance.
Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease.
About the EyeArt® AI Eye Screening System
The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested in the real-world on more than half million patients and nearly two million retinal images globally.
The EyeArt AI Eye Screening System was developed with funding from the US National Institutes of Health (NIH) and is validated by the UK National Health Service (NHS). The EyeArt System has CE marking in the EU and a Health Canada license. In the US, the EyeArt System is limited to investigational use only.
Brands: EyeArt® AI System